RxDoctor Payments Data

Jayakrishna Madabushi

Psychiatry · Birmingham, ALNPI 1982836045

Payments from drug & device makers

$639in general payments, 2019–2025

Across 34 payments — averaging $18.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$184
  • Sunovion Pharmaceuticals Inc.$110
  • Novo Nordisk$98
  • Vanda Pharmaceuticals Inc.$70
  • Lundbeck LLC$54
  • Otsuka America Pharmaceutical, Inc.$42
  • plus $80 from 6 others

What the payments were for

  • Food & beverage$639100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$639 in reported general payments places this provider in the 45th percentile of 400 psychiatry providers in Alabama.

See all psychiatry providers in Alabama

Medicare billing

Part B allowed, 2024
$791,240
Medicare patients
546
Services billed
10,012

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban12$6,856
Clonazepam647$5,036
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine109$4,983
VyvanseLisdexamfetamine Dimesylate13$4,961
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine96$3,114
Dexmethylphenidate Hcl ErDexmethylphenidate Hcl18$2,127
Lorazepam277$1,842
Alprazolam388$1,666
Divalproex Sodium49$1,543
Clozapine20$1,192
Memantine Hcl36$1,189
Olanzapine39$977
Quetiapine Fumarate72$888
Atorvastatin Calcium94$834
Mirtazapine33$682

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$16$4,96113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 400 psychiatry providers in Alabama.

Other psychiatry in Birmingham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →